Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CMRX

Chimerix (CMRX) Stock Price, News & Analysis

Chimerix logo

About Chimerix Stock (NASDAQ:CMRX)

Advanced Chart

Key Stats

Today's Range
$8.54
$8.54
50-Day Range
$8.54
$8.54
52-Week Range
$0.75
$8.55
Volume
N/A
Average Volume
2.94 million shs
Market Capitalization
$801.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.53
Consensus Rating
Hold

Company Overview

Chimerix Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
13th Percentile Overall Score

CMRX MarketRank™: 

Chimerix scored higher than 13% of companies evaluated by MarketBeat, and ranked 901st out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Chimerix has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Chimerix has received no research coverage in the past 90 days.

  • Read more about Chimerix's stock forecast and price target.
  • Earnings Growth

    Earnings for Chimerix are expected to grow in the coming year, from ($0.99) to ($0.85) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Chimerix is -9.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Chimerix is -9.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Chimerix has a P/B Ratio of 3.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for CMRX.
  • Dividend Yield

    Chimerix does not currently pay a dividend.

  • Dividend Growth

    Chimerix does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for CMRX.
    • Insider Buying vs. Insider Selling

      In the past three months, Chimerix insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      13.10% of the stock of Chimerix is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      45.42% of the stock of Chimerix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Chimerix's insider trading history.
    Receive CMRX Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter.

    By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

    CMRX Stock News Headlines

    Musk’s Project Colossus could mint millionaires
    I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.tc pixel
    Chimerix reports Q4 EPS (25c), consensus (28c)
    See More Headlines

    CMRX Stock Analysis - Frequently Asked Questions

    Chimerix, Inc. (NASDAQ:CMRX) issued its quarterly earnings data on Friday, March, 21st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.01. The biopharmaceutical company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.31 million.

    Chimerix's top institutional investors include Koshinski Asset Management Inc. (0.09%), Moore Capital Management LP and Group One Trading LLC. Insiders that own company stock include Michael T Andriole, Michael Albert Alrutz, Michelle Laspaluto, Allen S Melemed, David Jakeman, Fred A Middleton, Martha J Demski and Robert J Meyer.
    View institutional ownership trends
    .

    Based on aggregate information from My MarketBeat watchlists, some other companies that Chimerix investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), CrowdStrike (CRWD), Pfizer (PFE) and Broadcom (AVGO).

    Company Calendar

    Last Earnings
    3/21/2025
    Today
    8/31/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:CMRX
    CIK
    1117480
    Employees
    90
    Year Founded
    2000

    Price Target and Rating

    High Price Target
    $8.55
    Low Price Target
    $8.50
    Potential Upside/Downside
    -0.1%
    Consensus Rating
    Hold
    Rating Score (0-4)
    2.00
    Research Coverage
    3 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    ($0.99)
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$82.10 million
    Net Margins
    N/A
    Pretax Margin
    -52,574.85%
    Return on Equity
    -50.78%
    Return on Assets
    -44.94%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    6.33
    Quick Ratio
    6.33

    Sales & Book Value

    Annual Sales
    $212 thousand
    Price / Sales
    3,778.71
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $2.17 per share
    Price / Book
    3.94

    Miscellaneous

    Outstanding Shares
    93,804,000
    Free Float
    78,154,000
    Market Cap
    $801.09 million
    Optionable
    Optionable
    Beta
    -0.17

    Social Links

    7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

    Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

    Get This Free Report

    This page (NASDAQ:CMRX) was last updated on 8/31/2025 by MarketBeat.com Staff
    From Our Partners